Purpose: Pregnant women and infants less than 6 months of age have a higher risk of complications from influenza. Vaccination is recommended for pregnant women to decrease risk of infection and hospitalizations between both the women themselves and infants. However, vaccination rates remain low in pregnant women. The objective of this study was to determine the association between having a usual source of care and seasonal influenza vaccination rates among women who were pregnant between 2012 and 2016.
Methods: A retrospective study was conducted using pooled data from the 2012-2016 Medical Expenditure Panel Survey. Frequencies of seasonal influenza vaccinations and other sociodemographic factors were estimated. A multivariable log-binomial regression model was used to examine the association between having a usual source of care and seasonal influenza vaccination rates.
Results: The weighted influenza vaccination rate among pregnant women was 54.5%. About one third did not have a usual source of care. The adjusted prevalence ratio of receiving an influenza vaccine for pregnant women without a usual source of care was 0.76 (95% confidence interval = 0.60-0.98). The top three main reasons for not having a usual source of care were being seldom or never sick (55.7%), not having health insurance (10.6%), and having recently moved to an area (9.9%).
Conclusions: Pregnant women without a usual source of care had significantly lower probability of being vaccinated against seasonal influenza. Improving access to care through greater insurance coverage, addressing cost barriers, and providing patient education may help improve vaccination rates in this population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pds.5394 | DOI Listing |
Pain Res Manag
January 2025
Statistics Unit, Riga Stradinš University, 16 Dzirciema Street, Riga LV-1007, Latvia.
Neuropathic pain (NP) is a chronic condition caused by abnormal neuronal excitability in the nervous system. Current treatments for NP are often ineffective or poorly tolerated. Hence, we reviewed the efficacy and safety of novel drugs or devices that target neuronal excitability in NP patients compared with placebo, sham, or usual care interventions.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
College of Health and Medicine, Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Objective: To evaluate the impact of absolute cardiovascular risk counselling on quality-of-life indices within a chest pain clinic.
Data Sources And Study Setting: Primary data was collected at the Royal Hobart Hospital, Australia, between 2014 and 2020.
Study Design: Patients attending an Australian chest pain clinic were randomised into a prospective, open-label, blinded-endpoint study over a minimum 12-months follow-up.
Sr Care Pharm
January 2025
3 Palm Beach Atlantic University Gregory School of Pharmacy, West Palm Beach, Florida.
Antibiotic lengths of therapy (LOT) vary widely, based on infection type, antibiotic regimen, and patient characteristics. Longer LOT are associated with increased risk of antibiotic resistance, adverse effects, and health care costs. There are increasing data supporting shorter LOT for many infections based on randomized, controlled trials (RCTs).
View Article and Find Full Text PDFJ Genet
January 2025
Programa de Pos-graduacao em Ciencias Biologicas (Genetica), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
A significant proportion of next-generation sequencing (NGS) data ends up not being used since they comprise information out-of-scope of the primary studies. This 'waste' of potential can be harnessed to explore organellar genomes, such as the mitochondrial DNA, and be used for evolutionary, conservation and biodiversity research. We present the complete mitochondrial genomes of the deep-sea methanotrophic sponges and (Demospongiae, Poecilosclerida) retrieved from previously published whole metagenome sequencing data.
View Article and Find Full Text PDFJ Health Econ Outcomes Res
December 2024
Jazz Pharmaceuticals UK Ltd., London, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!